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Introduction: Mastectomy for breast cancer may bring the patient to develop long term issues concerning
the psychological and physical status. Immediate breast reconstruction (IBR) should be considered and
proposed by physicians as an integrated procedure in the surgical approach to breast cancer to reduce
further surgery. Acellular dermal matrix (ADM) has been used in revision breast reconstruction for fold
malposition, capsular contracture and rippling also, showing good outcomes with low risk of compli-
cations. Aim of this study was to verify if the known advantages in using ADM for IBR would led to lower
rates of seroma formation, infection, skin ﬂap necrosis and overall complication related to the implant.
Methods: We performed a prospective study, including all consecutive patients undergone to IBR with
biological graft with ADM between January 2012 and January 2013 at our Institution. Data on major
issues of the patients and complications were recorded. All patients underwent to IBR with ADM
(Tutomesh) implant with or without ﬁbrin sealant positioning.
Results: A total of 24 patients underwent 28 immediate breast reconstruction with Tutomesh ADM
implant. Main postoperative complications included seroma formation in 20.8% (5 pts), infection in 8.3%
(2 pts) and hematoma in 4.2% (1 pt). There were any skin ﬂap necrosis in the study. Diabetes was
associated in two cases with edema and ecchymosis; hypertension with infection in one case (implant
removal) and seroma in one case. First class of obesity (BMI 30e32.7) was associated with seroma in 3
cases, and with infection in one. In patient without ﬁbrin sealant (12 patients e 13 breasts) complica-
tions were represented by hematoma (1 pt. 4.2%), infection (1 pt. 4.2%; implant removal) and seroma (4
pts 16.8%).
Conclusions: The use of Tutomesh® bovine pericardium for immediate breast is safe and technically
useful. Complications rate is not high, except for seroma formation that can be reduced by the
contemporary use of ﬁbrin sealant.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Mastectomy for breast cancer may bring the patient to develop
long term issues concerning the psychological and physical status
[1]. Thus, the request for immediate post mastectomy breast
reconstruction and the related options for surgical products to
replace soft tissues, have simultaneously grown in the last decade
[2]. Immediate breast reconstruction (IBR) should be considered
and proposed by physicians as an integrated procedure in the
surgical approach to breast cancer to reduce further surgery [3].giero).
f of Surgical Associates Ltd.Skin Sparing Mastectomy (SSM) with IBR has a good impact on
quality of life and self-esteem, providing good esthetic outcomes
without lowering the local oncological safety [4,5]. IBR after SSM
has an acceptable local recurrence rate compared with conven-
tional mastectomy, no evidence of increased postmastectomy pain
syndrome (PMPS) compared to mastectomy alone, but the risk of
local postoperative complications is still real [6e9]. The advantages
in using acellular dermal matrix (ADM) as pectoral extenders
versus complete submuscular coverage, include the capability to
facilitate to direct implant reconstruction, improve the inframam-
mary and lateral mammary fold deﬁnition and decrease rates of
capsular contracture. It works as a tissue support, protective against
radiation damages and helpful in the correction of secondary breast




(n ¼ 24, 28 breast)
Mean age 54,00 years Var 82,5217; Std Dev. 9,0841
Mean BMI 27,3083 Var 27,3083; Std Dev. 7,5671
Diabetes 12.5% (3 pts)




Smokers 37.5% (9 pts)
Fibrin sealant 50% (12 pts)
Mean duration of drain 5,1250 (days) Var12,0272; Std Dev3,4680
Implant removal 4.2% (1 pt)
Chemotherapy 24 (100%) AC p 5e20.8%; AT CMF 3e12.5%;
Orm. 16e66.7%*
Radiation therapy 0
Mean follow up 15,5 months Var 18,6087; Std Dev 4,3138
Table 2
Postoperative complications.







Total complication by breasts 10 (41.6%)
A. Gubitosi et al. / International Journal of Surgery 12 (2014) S205eS208S206to the patients the opportunity of a complete one stage demolitive/
reconstructive operation. ADM has been used in revision breast
reconstruction for fold malposition, capsular contracture and
rippling also, showing good outcomes with low risk of complica-
tions [8,14].
Aim of this study was to verify if the known advantages in using
ADM for IBR would led to lower rates of seroma formation, infec-
tion, skin ﬂap necrosis and overall complication related to the
implant.
2. Methods
We performed a prospective study, including all consecutive
patients undergone to IBR with biological graft with ADM between
January 2012 and January 2013 at Department of Surgery, Second
University of Naples. Patient who underwent breast reconstruction
with a biological graft other than Tutomesh® or patient with other
type of reconstruction were excluded from the study.
Data on major issues of the patients (age, BMI, surgical features,
radio and chemotherapy, comorbidities) were prospectively
collected. All complications (seroma, hematoma, infection and
need for implant removal) were recorded; ecchymosis and edema
were consideredminor complications. Preoperative antibiotic short
term prophylaxis was used for all the patients (Ceftriaxone 2gr i.v.
1 h before surgery).
The surgical technique utilized for immediate breast recon-
struction by a submuscular implant was carried out by suturing the
mesh to the inframammary fold, caudal edge of the pectoralis
muscle and laterally to the serratus anterior muscle to reach the
complete inferior pole coverage, using two meshes when needed.
ADM used in our series was a collagene membrane extracted from
solvent-preserved bovine pericardium (Tutomesh® by Tutogen e
Neunkirchen am Brand e Germany) subject to a multiple step
puriﬁcation process (“Tutoplast Process”) and sterilized by gamma
irradiation. Tutoplast Process consists of a thorough puriﬁcation of
the tissue and gentle tissue-conserving solvent dehydration [15].
The mesh has a size of 60  80 mm.
Fibrin sealant was sprayed between mesh and tissue when
needed. A drain was used on all patients.
Statistics were accomplished by the use of dedicated software
(SPSS ver 17).
3. Results
A total of 24 patients underwent 28 immediate breast recon-
struction with Tutomesh ADM implant over a period of 12 months.
Patients characteristics are shown in Table 1. Mean age was 54.0
years (26e70ys); nine patients were smokers; incidence of
comorbidities (all under medical control) are depicted in Table 1;
chemotherapy was administered postoperatively in 16 cases (75%);
8 patients had chemotherapy before surgery. Fibrin sealant was
sprayed between mesh and tissue in 12 patients (15 breasts).
Main postoperative complications included seroma formation in
17.8% (5 pts), infection in 7.1% (2 pts) and hematoma in 3.5% (1 pt).
Seroma cases did not require any surgery or implant removal. He-
matoma was drained after 24 h from surgery. There were any skin
ﬂap necrosis in the study, while ecchymosis were registered in one
patient, and edema in one, both of them regressed without any
therapy in 14 days. All complications are summarized in Table 2.
The mean duration of drain in all patients was 5 days, in 7 cases it
was longer; in 5 patients who developed seroma, and in two sub-
ject with infection, the mean duration of drain placement was 11
and 10.5 days, respectively. One case of infection regressed
promptly with drain and antibiotic therapy (Staphylococcus), the
other one required implant removal. The mean duration of followup was 15.5 months; two patients were lost at the follow up at 5
and 7 months.
Comorbidities have been matched with postoperative compli-
cations. Diabetes was associated in two cases with edema and
ecchymosis; hypertension with infection in one case (implant
removal) and seroma in one case. First class of obesity (BMI
30e32.7) was associated with seroma in 3 cases, and with infection
in one (no implant removal). Between the nine smoker patients 2
had complications (edema, infection). In the group with ﬁbrin
sealant (12 patients e 15 breasts), complications were represented
by infection (1 pt. 6.6%), seroma (1 pt. 6.6%), ecchymosis (1 pt. 6.6%)
and edema (1 pt. 6.6%).
In patients without ﬁbrin sealant (12 patients e 13 breasts),
complications were represented by hematoma (1 pt. 7.7%), infec-
tion (1 pt. 7.7%; implant removal) and seroma (4 pts 30.7%). The
overall complications rate in the two groups of patients was
respectively 13.3% and 46.6%.4. Discussion
The use of acellular dermal matrix has been adopted by many
surgeons in several surgical ﬁelds [16e19] when a dermal rein-
forcement was needed. In reconstructive and revisionary breast
surgery ADM use offers several technical advantages (capability to
facilitate to direct implant reconstruction, improve the inframam-
mary and lateral mammary fold deﬁnition and decrease rates of
capsular contracture). The major advantage originating from the
three-dimensional acellular collagen structure that operate an
inducement to the attraction of ﬁbroblasts and promotion of their
replication. Tissue integration of the mesh by reparative processes
of ﬁbrosis and angiogenesis follows; three-dimensional collagen
structure result as a scaffold for the ingrowth of the patient's own
tissue. Thus ADM works as a tissue reinforcement and anatomical
folds support. It ensues to be protective against radiation damages
Table 3
Comparison of complication rates with Veritas and Alloderm.
Postoperative complications Tutomesh ® no ﬁbrin
sealant n13br 12 pts
Tutomesh® þ ﬁbrin
sealant n15br e 12 pts
Veritas® n93br (Moﬁd et al. 2012) [27] Alloderm ® n269br (Chun et al.2010) [21]
Hematoma 1 (7.7%) 0 2 (2.2%) 6 (2.2%)
Infection 1 (7.7%) 1 (6.6%) 6 (6.65%) 24 (8.9%)
Seroma 4 (30.7%) 1 (6.6%) 7 (7.5%) 38 (14.1%)
S.F. necrosis 0 0 5 (5.54%) 63 (23.4%)
Total complication by breasts 6 (46.1%) 2 (13.3%) 20 (1.5%) 131 (48.7%)
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[10e13].
We used an acellular dermal membrane extracted from solvent-
preserved bovine pericardium (Tutomesh® by Tutogen e Neu-
nkirchen am Brand e Germany). It is a thin fenestrated bovine
pericardium non-crosslinked acellular collagen matrix. Mesh-
Perforation intent is to decrease the incidence of seromas, still
present in many series [20,21]. Seroma occurrence has reported to
be 6.5%, ranging from 0 to 15.4% [22,23]. Our intent was to reduce
seroma formation using sprayed ﬁbrin sealant between dissected
tissues and dermal matrix to obtain adhesion of the mesh and a
synergic stimulus on tissue healing. Human ﬁbrin glue is without
any doubt a valuable adjuvant to surgery as a measure against
complications. The application of ﬁbrin sealant not only can facili-
tate the hemostasis but, due to the glue biological properties
stimulating ﬁbrosis and angiogenesis, it can also synergize the
stimulus promoted by collagen mesh. It reduces secretion from
dissected tissues decreasing seroma formation [24]. It is important
to not forget the indirect effect ﬁbrin glue has against infection, due
to its ability to ﬁll dead space, which might otherwise provide
nourishment for bacteria [25,26]. In Table 3 a comparison of com-
plications between the two groups of our series (with or without
ﬁbrin sealant) and two studies with different ADM is shown [27]. In
our series the all complications rate is lower in the groupwith ﬁbrin
sealant. In the same group seroma and infection rate are lower than
in the series with Veritas® or Alloderm®. Obesity represents an
important risk factor for the incidence of complications, in partic-
ular for seroma formation.
5. Conclusions
The use of Tutomesh® bovine pericardium for immediate breast
is safe and technically useful. Complications rate is not high, except
for seroma formation that can be reduced by the contemporary use
of ﬁbrin sealant. Obesity represents the main comorbidity related
to seroma formation. Additional studies are needed to conﬁrm
these outcomes.
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